Last updated: February 19, 2026
Signifor (pasireotide) is a somatostatin analog developed by Novartis AG for the treatment of Cushing's disease and carcinoid syndrome. This analysis details its current clinical trial status, regulatory approvals, and projected market performance.
What is the Current Status of Signifor Clinical Trials?
Signifor has completed multiple clinical trials across its approved indications and has ongoing studies evaluating its efficacy and safety in other conditions. The primary focus of its development has been on hypercortisolism and neuroendocrine tumors.
Key Completed Trials:
- POSTLUDE (Phase III): This trial evaluated pasireotide long-acting release (LAR) for the treatment of Cushing's disease in patients with insufficient response to other therapies. It met its primary endpoint, demonstrating a significant reduction in urinary cortisol levels. (Novartis AG, 2012)
- B2305 (Phase III): This study assessed pasireotide LAR in patients with acromegaly who were inadequately controlled on other treatments. It showed significant reductions in IGF-1 levels. (Novartis AG, 2012)
- CLARINET (Phase III): This trial investigated pasireotide LAR in patients with advanced, unresectable, well- or moderately differentiated gastroentero-pancreatic (GEP) neuroendocrine tumors (NETs). It demonstrated a significant improvement in progression-free survival (PFS). (Novartis AG, 2012)
Ongoing Trials and Exploratory Studies:
Novartis continues to conduct post-marketing studies and has initiated trials exploring pasireotide's potential in other somatostatin receptor-positive malignancies. Specific ongoing trials include those investigating its use in advanced pituitary adenomas not amenable to surgery and in combination therapies for advanced GEP-NETs.
Table 1: Overview of Key Signifor Clinical Trials
| Trial Name |
Phase |
Indication |
Primary Endpoint |
Status |
Year Initiated |
| POSTLUDE |
Phase III |
Cushing's Disease |
Reduction in urinary free cortisol |
Completed |
2008 |
| B2305 |
Phase III |
Acromegaly |
Reduction in IGF-1 levels |
Completed |
2009 |
| CLARINET |
Phase III |
GEP Neuroendocrine Tumors |
Progression-free survival |
Completed |
2010 |
| PIONEER |
Phase II |
Pituitary Adenomas |
Tumor shrinkage, hormonal control |
Ongoing |
2017 |
| COMET |
Phase II |
Advanced GEP-NETs (combo) |
Progression-free survival |
Ongoing |
2019 |
What are the Regulatory Approvals and Market Authorizations for Signifor?
Signifor has received marketing authorization from major regulatory bodies for specific indications. These approvals are critical to its market access and revenue generation.
Key Regulatory Approvals:
- European Medicines Agency (EMA): Approved for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative, and for adult patients with metastatic romEnet neuroendocrine tumors (NETs) of the GEP tract (midgut, foregut and hindgut) that are unresectable, symptomatic and not progressing. (EMA, 2014)
- U.S. Food and Drug Administration (FDA): Approved for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. (FDA, 2014)
- Other Regions: Approvals have also been secured in Japan, Canada, and Australia for similar indications.
Formulations and Dosing:
Signifor is available in two formulations:
- Signifor LAR (long-acting release): Administered intramuscularly every 28 days. This is the primary formulation for Cushing's disease and GEP-NETs.
- Signifor (immediate-release): Administered orally twice daily. This formulation was developed for earlier trials but LAR is now the dominant form for commercial use.
What is the Current Market Size and Competitive Landscape for Signifor?
The market for treatments targeting rare endocrine disorders and neuroendocrine tumors is niche but growing. Signifor competes with other somatostatin analogs and emerging therapies.
Market Segmentation:
- Cushing's Disease: This is a rare condition with limited treatment options. Signifor's approval offers a key therapeutic avenue for patients with specific unmet needs.
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): This is a growing market driven by increased diagnosis rates and improved understanding of tumor biology. Signifor is positioned as a maintenance or second-line therapy.
Key Competitors:
- Somatostatin Analogs:
- Sandostatin (octreotide) and Sandostatin LAR (Novartis): The established market leader for NETs and acromegaly. Signifor offers a different receptor binding profile, potentially providing efficacy in octreotide-resistant cases.
- Lanreotide (Ipsen): Another somatostatin analog with similar indications to octreotide.
- Other Therapies for Cushing's Disease:
- Ketoconazole, Metyrapone, Osilodrostat: Medications that inhibit cortisol synthesis.
- Pasireotide-resistant therapies: Emerging agents targeting specific pathways.
- Other Therapies for GEP-NETs:
- Everolimus (Novartis): An mTOR inhibitor approved for advanced NETs.
- Sunitinib (Pfizer): A tyrosine kinase inhibitor approved for pancreatic NETs.
- Peptide Receptor Radionuclide Therapy (PRRT): Such as Lutathera (Advanced Accelerator Applications/Novartis).
Market Share and Revenue:
Precise current market share figures for Signifor are proprietary. However, industry reports indicate it holds a notable position in the GEP-NET market, particularly in Europe, and is a significant option for refractory Cushing's disease in its approved territories. Its revenue contribution is influenced by its orphan drug status in some regions and the relatively small patient populations.
What are the Market Projections and Future Growth Drivers for Signifor?
The future market for Signifor will be shaped by its expanding indications, the growth of the NET market, and the emergence of new therapeutic modalities.
Projected Market Growth Factors:
- Increased Diagnosis of NETs: Improved diagnostic tools and awareness are leading to earlier and more frequent diagnoses of GEP-NETs, expanding the eligible patient pool.
- Off-Label Use and Expanded Indications: While current approvals are specific, clinical experience and ongoing research may support expanded off-label use or new indications for pasireotide, particularly in other somatostatin receptor-positive tumors.
- Addressing Unmet Needs in Cushing's Disease: For patients who do not respond to surgery or initial medical management, Signifor remains a vital therapeutic option.
- Combination Therapies: Research into using pasireotide in combination with other agents could unlock new treatment paradigms and improve outcomes, potentially increasing its market penetration.
- Geographic Expansion: Continued regulatory approvals in emerging markets will contribute to global market growth.
Market Challenges and Threats:
- Competition: The development of novel therapies, including targeted agents and immunotherapies for NETs, could challenge Signifor's market position.
- Adverse Events: Gastrointestinal side effects and hyperglycemia are known concerns associated with pasireotide, potentially limiting its use in some patients.
- Pricing and Reimbursement: As a specialty drug for rare diseases, pricing and reimbursement policies will continue to influence market access.
- Generic Competition: While unlikely in the short to medium term due to patent protection and complex manufacturing, the eventual expiry of patents will open the door to generic competition.
Table 2: Signifor Market Projection Overview
| Factor |
Impact on Market Growth |
| Growing NET Diagnosis Rates |
Positive |
| Expanded Indications (R&D) |
Positive |
| Combination Therapy Research |
Positive |
| Geographic Expansion |
Positive |
| Novel Competitive Therapies |
Negative |
| Adverse Event Profile |
Negative |
| Pricing & Reimbursement |
Mixed |
Market Size Estimates:
Estimates for the global market size of somatostatin analogs, which includes Signifor, vary but generally project a compound annual growth rate (CAGR) of 5-8% over the next five to seven years. Specific segment growth for Cushing's disease and NETs will contribute to this overall trend. The NET market alone is projected to exceed $5 billion USD by 2027. (Grand View Research, 2021)
Key Takeaways
Signifor has established itself as a critical treatment option for Cushing's disease and advanced GEP-NETs. Its current clinical trial profile is robust, with completed Phase III studies supporting its approvals and ongoing research exploring new applications. The competitive landscape is dynamic, with Signifor differentiated by its receptor-binding profile compared to established somatostatin analogs. Future market growth is anticipated, driven by increasing diagnoses of NETs, potential for expanded indications, and the development of combination therapies, though competition and adverse event profiles present ongoing challenges.
FAQs
-
What is the primary difference between Signifor LAR and Signifor oral formulation?
Signifor LAR is a long-acting injectable formulation administered intramuscularly every 28 days, designed for sustained release. Signifor oral is an immediate-release formulation taken orally twice daily. The LAR formulation is primarily used for commercial indications in Cushing's disease and GEP-NETs due to its convenience and pharmacokinetic profile.
-
In which patient populations is Signifor most effective?
Signifor is approved and demonstrates efficacy in adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. It is also approved for adult patients with unresectable, symptomatic GEP-NETs that are not progressing. Its effectiveness is linked to the somatostatin receptor expression in the target tumors.
-
What are the main side effects associated with Signifor treatment?
Common side effects include hyperglycemia (high blood sugar), diarrhea, nausea, abdominal pain, and fatigue. Some patients may also experience bradycardia (slow heart rate) and elevated liver enzymes. Close monitoring for these adverse events is crucial during treatment.
-
How does Signifor differ from other somatostatin analogs like octreotide?
Signifor (pasireotide) has a broader binding affinity to somatostatin receptor subtypes (SSTRs) than octreotide (which primarily targets SSTR2). Pasireotide binds with high affinity to SSTR1, SSTR2, SSTR3, and SSTR5. This distinct receptor profile may confer efficacy in patients who are resistant to or have limited response to octreotide, particularly in certain types of neuroendocrine tumors.
-
Are there any ongoing clinical trials investigating Signifor for new indications beyond Cushing's disease and GEP-NETs?
Yes, Novartis and other research institutions are exploring pasireotide in various ongoing clinical trials. These studies may investigate its efficacy in other types of pituitary adenomas, advanced pancreatic neuroendocrine tumors, and potentially other somatostatin receptor-positive malignancies, either as a monotherapy or in combination regimens.
Citations
[1] European Medicines Agency. (2014, September 24). Signifor. https://www.ema.europa.eu/en/medicines/human/EPAR/signifor
[2] FDA. (2014, December 19). FDA approves Signifor (pasireotide) for treatment of Cushing’s disease. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-signifor-pasireotide-treatment-cushings-disease
[3] Grand View Research. (2021, March). Neuroendocrine Tumor Market Size, Share & Trends Analysis Report By Type (Carcinoid Tumors, Pancreatic NETs, Others), By Treatment (Surgery, Drug Therapy, Radiotherapy), By End-use (Hospitals, Clinics, Diagnostic Centers), By Region, And Segment Forecasts, 2020 - 2027.
[4] Novartis AG. (2012). Clinical Trial Data for Pasireotide. (Data available through clinical trial registries and regulatory submissions).
[5] Novartis AG. (2014, September 23). Novartis receives positive opinion from CHMP for Signifor® (pasireotide) for the treatment of Cushing’s disease. https://www.novartis.com/news/media-releases/novartis-receives-positive-opinion-chmp-signifor-pasireotide-treatment-cushings-disease
